BridgeBio Oncology Therapeutics, Inc. (BBOT) company profile
Close on Nov 13, 2026Market cap $171.57MP/E –Yield –
About BridgeBio Oncology Therapeutics
Pharmaceutical Preparations, SIC 2834
BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops targeted therapies for patients with cancers driven by RAS and PI3Kα oncogenes. The company focuses on addressing conditions such as lung, breast, pancreatic, and colon cancers. Its pipeline consists of orally bioavailable small-molecule inhibitors designed to target active and inactive conformations of oncogenic drivers. Its key development programs include BBO-8520, an inhibitor targeting KRAS G12C in non-small cell lung cancer; BBO-11818, a pan-KRAS inhibitor addressing various KRAS mutations; and BBO-10203. The company currently has no commercialized products, and its treatments are intended for oncology patients with specific genetic mutations.
The company operates within the United States and evaluates its pipeline through clinical trials, including the ONKORAS-101 and KONQUER-101 studies in patients with locally advanced or metastatic solid tumors. BridgeBio Oncology Therapeutics maintains its principal executive offices in South San Francisco, California.
Summary of the business section of BridgeBio Oncology Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BridgeBio Oncology Therapeutics, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 256 E. Grand Avenue, Suite 104 94080
- Phone
- (857) 702-0377
- Website
- bbotx.com
- Employees
- 92, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche, LLP, San Francisco, CA
Stock & identifiers
- Ticker
- BBOT
- Former tickers
- HLXB until Aug 13, 2025
- Exchange
- Nasdaq
- IPO date
- Feb 13, 2024
- Shares outstanding
- 80M, Aug 6, 2026
- Public float
- $465.15M, Aug 13, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1869105
- CUSIP
- G4444H101
- FIGI
- BBG01L3GYF02
- Share class FIGI
- BBG01L3GYF11
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Pedro Beltran | President and CEO, Director | 43,529 |
| Eli M. Wallace | Chief Executive Officer, Director | – |
| Marc Cobo | Principal Accounting Officer | 13,812 |
| Idan Elmelech | COO & Principal Financial Ofcr | 14,152 |
| Yong Ben | Chief Med & Dev Officer | 43,529 |
| Caleb Tripp | Chief Financial Officer | – |
| Nebojsa Obradovic | Chief Legal Officer | – |
| Bihua Chen | Director | 18,782,194 |
| Praveen P. Tipirneni | Director | – |
| Neil Kumar | Director | – |
| Peter F. Lebowitz | Director | – |
| Frank McCormick | Director | – |
| Jake Bauer | Director | – |
| Raymond J. Kelleher | Director | – |
| Michelle Doig | Director | – |
| Holdings II LLC Helix | Director | 4,989,000 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Eli Wallace Former President and Chief Executive Officer | $571.85K | $256.78K | $7.65M | $3.00M | $14.00K | $11.49M | +157% |
| Uneek Mehra Former Chief Financial Officer | $233.19K | $179.03K | $4.13M | – | $12.53K | $4.56M | – |
| Yong Ben Chief Medical and Development Officer | $525.30K | $231.66K | $2.46M | – | $14.00K | $3.23M | +122% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Feb 13, 2024
- Offer price
- $10.00
- Exchange
- Nasdaq
- First trading day
- Feb 12, 2024
- First-day close
- $10.55+5.5%
- Lock-up ends (est.)
- Aug 10, 2024
“This is an initial public offering of our Class A ordinary shares, par value $0.0001 per share, which we refer to as our public shares, at an initial public offering price of $10.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 92 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 13, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 13, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 6, 2025 | Name change | Name changed from Helix Acquisition Corp. II to BridgeBio Oncology Therapeutics, Inc. |
| Jun 20, 2025 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Feb 13, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 8, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?